Sequenta, Inc.’s ClonoSIGHT Test Validated In Multiple Myeloma By Data To Be Presented At Annual Meeting Of The American Society of Hematology
Published: Dec 09, 2013
Sequenta, Inc. today announced that researchers will present data at the 55th annual meeting of the American Society of Hematology (ASH) demonstrating that Sequenta’s ultra-sensitive method for minimal residual disease (MRD) detection is prognostic for both time to tumor progression (TTP) and overall survival (OS) in patients who have been treated for multiple myeloma (MM).
Help employers find you! Check out all the jobs and post your resume.